Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Treasury Shares (2022 - 2025)

SAB Biotherapeutics' Treasury Shares history spans 4 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $5.5 million, changed 0.0%, while the annual FY2025 figure was $5.5 million, 0.0% changed from the prior year.
  • Treasury Shares reached $54665.0 in Q4 2025 per SABSW's latest filing, up from $18818.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $668875.0 in Q1 2023 to a low of -$54665.0 in Q4 2023.
  • Average Treasury Shares over 4 years is $196385.9, with a median of $54665.0 recorded in 2022.
  • The largest YoY upside for Treasury Shares was 0.0% in 2023 against a maximum downside of 0.0% in 2023.
  • A 4-year view of Treasury Shares shows it stood at $5.5 million in 2022, then changed by 0.0% to $5.5 million in 2023, then changed by 0.0% to $5.5 million in 2024, then changed by 0.0% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Treasury Shares are $5.5 million (Q4 2025), $5.5 million (Q3 2025), and $5.5 million (Q2 2025).